Table I.
Characteristics of study isolates.
| Clinical antimicrobial susceptibility | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NOx | PT | Date of strain separated | Ward | TZP | CAZ | SCF | ATM | IPM | AK | FEP | MEM | TIM | CIP | SXT | CTX | LEV | CN | SAM |
| 1AI | 51M | 3/9 | 3 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 2AI | 13M | 3/9 | 4 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 3BI | 46M | 3/23 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 4AI | 64M | 3/22 | 10 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 5AI | 34M | 3/11 | 8 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 6BI | 1M | 3/17 | 3 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 7CI | 65M | 3/12 | 1 | R | R | R | R | R | R | R | R | R | R | R | R | I | R | R |
| 8AI | 7M | 5/14 | 4 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 9DI | 88F | 3/31 | 6 | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| 10BI | 33F | 3/28 | 3 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 11BII | 25F | 3/30 | 3 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 12BII | 48F | 3/28 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 13BII | 30F | 3/28 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 14BII | 47F | 4/2 | 2 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 15BII | 55M | 4/21 | 3 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 16BIV | 25M | 4/21 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 17AII | 63M | 3/20 | 1 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 18BI | 72F | 3/23 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 19CI | 57M | 3/12 | 1 | R | R | R | R | R | R | R | R | R | R | R | R | I | R | R |
| 20AI | 78M | 3/18 | 1 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 21AII | 41M | 3/10 | 4 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 22EII | 80F | 3/30 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | I | R |
| 23FI | 46M | 4/5 | 4 | R | R | I | R | R | R | I | R | R | R | R | R | R | R | R |
| 24BII | 43M | 4/3 | 9 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 25AII | 55M | 4/5 | 5 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 26AII | 55M | 4/6 | 5 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 27BII | 57F | 4/7 | 2 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 28AI | 70F | 4/7 | 2 | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R |
| 29DII | 69M | 4/5 | 2 | R | R | S | R | R | R | R | R | R | R | R | R | R | R | R |
| 30GII | 87F | 2/28 | 1 | R | S | R | R | R | R | R | R | R | R | R | R | R | S | S |
| 31BIII | 56M | 2/28 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 32BI | 6F | 2/28 | 7 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 33BI | 27M | 3/4 | 1 | R | R | I | R | R | R | R | R | R | R | R | R | R | R | R |
| 34HI | 79M | 2/28 | 1 | R | S | I | R | R | R | R | R | R | R | R | R | R | R | R |
PT, patient age and sex. Wards: 1, Intensive care unit; 2, Department of Respiratory; 3, Cardiothoracic surgery; 4, Orthopedics; 5, Neurology; 6, Geriatric Ward; 7, Department of Minimally Invasive Surgery; 8, Neurosurgery; 9, Urology; 10, Digestive system department. Antimicrobials: TZP, piperacillin/tazobactam; CAZ, ceftazidime; SCF, cefoperazone/sulbactam; ATM, aztreonam; IPM, imipenem; AK, amikacin; FEP, cefepime; MEM, meropenem; TIM, ticarcillin/clavulanic acid; CIP, ciprofloxacin; SXT, trimethoprim/sulfamethoxazole; CTX, cefotaxime; LEV, levofloxacin; CN, gentamicin; SAM, ampicillin/sulbactam. NOx: The isolates were classified into 8 phenotypes (A-H) according to their susceptibility to the tested clinical antimicrobials; A, resistant to all the aforementioned drugs; B, only intermediate to SCF; C, only intermediate to LEV; D, only susceptible to SCF; E, intermediate to SCF and CN; F, intermediate to SCF and FEP; G, susceptible to CAZ, CN and SAM; H, susceptible to CAZ and intermediate to SCF; R, resistance; I, intermediary; S, sensitivity.